Future studies should explore: (i) whether TFNAs can be developed as an effective treatment for chronic CLD; (ii) the optimal stage of disease progression for TFNAs administration; and (iii) the potential efficacy of TFNAs in combination with other therapeutic agents, such as FXR agonists, to enhance treatment outcomes. The gene discussed is NR1H4; the disease is congenital secretory chloride diarrhea 1.